-
1
-
-
0035043972
-
The gastrins: Their production and biological activities
-
Dockray GJ, Varro A, Dimaline R, Wang T,. The gastrins: their production and biological activities. Annu Rev Physiol 2001; 63: 119-139.
-
(2001)
Annu Rev Physiol
, vol.63
, pp. 119-139
-
-
Dockray, G.J.1
Varro, A.2
Dimaline, R.3
Wang, T.4
-
2
-
-
34347373469
-
Attack and defence in the gastric epithelium - A delicate balance
-
Dimaline R, Varro A,. Attack and defence in the gastric epithelium-a delicate balance. Exp Physiol 2007; 92: 591-601.
-
(2007)
Exp Physiol
, vol.92
, pp. 591-601
-
-
Dimaline, R.1
Varro, A.2
-
3
-
-
44649104570
-
Control of gastric acid secretion in health and disease
-
Schubert ML, Peura DA,. Control of gastric acid secretion in health and disease. Gastroenterology 2008; 134: 1842-1860.
-
(2008)
Gastroenterology
, vol.134
, pp. 1842-1860
-
-
Schubert, M.L.1
Peura, D.A.2
-
4
-
-
0034960085
-
Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis
-
Ligumsky M, Lysy J, Siguencia G, Friedlander Y,. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol 2001; 33: 32-35.
-
(2001)
J Clin Gastroenterol
, vol.33
, pp. 32-35
-
-
Ligumsky, M.1
Lysy, J.2
Siguencia, G.3
Friedlander, Y.4
-
5
-
-
17844368379
-
Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa
-
European Rabeprazole Study Group
-
Rindi G, Fiocca R, Morocutti A, Jacobs A, Miller N, Thjodleifsson B, European Rabeprazole Study Group. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Eur J Gastroenterol Hepatol 2005; 17: 559-566.
-
(2005)
Eur J Gastroenterol Hepatol
, vol.17
, pp. 559-566
-
-
Rindi, G.1
Fiocca, R.2
Morocutti, A.3
Jacobs, A.4
Miller, N.5
Thjodleifsson, B.6
-
6
-
-
0033958779
-
Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach
-
Stolte M, Meining A, Seifert E, Alexandridis T,. Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach. Pathol Res Pract 2000; 196: 9-13.
-
(2000)
Pathol Res Pract
, vol.196
, pp. 9-13
-
-
Stolte, M.1
Meining, A.2
Seifert, E.3
Alexandridis, T.4
-
7
-
-
0030468499
-
Marked increase in gastric acid secretory capacity after omeprazole treatment
-
Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK,. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39: 649-653.
-
(1996)
Gut
, vol.39
, pp. 649-653
-
-
Waldum, H.L.1
Arnestad, J.S.2
Brenna, E.3
Eide, I.4
Syversen, U.5
Sandvik, A.K.6
-
8
-
-
0032924619
-
Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status
-
Gillen D, Wirz AA, Ardill JE, McColl KE,. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116: 239-247.
-
(1999)
Gastroenterology
, vol.116
, pp. 239-247
-
-
Gillen, D.1
Wirz, A.A.2
Ardill, J.E.3
McColl, K.E.4
-
9
-
-
67649222366
-
Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy
-
Reimer C, Sondergaard B, Hilsted L, Bytzer P,. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137: 80-87.
-
(2009)
Gastroenterology
, vol.137
, pp. 80-87
-
-
Reimer, C.1
Sondergaard, B.2
Hilsted, L.3
Bytzer, P.4
-
10
-
-
77954424083
-
Dyspeptic symptom development after discontinuation of a proton pump inhibitor: A double-blind placebo-controlled trial
-
Niklasson A, Lindstrom L, Simren M, Lindberg G, Bjornsson E,. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010; 105: 1531-1537.
-
(2010)
Am J Gastroenterol
, vol.105
, pp. 1531-1537
-
-
Niklasson, A.1
Lindstrom, L.2
Simren, M.3
Lindberg, G.4
Bjornsson, E.5
-
11
-
-
33750000586
-
Pathogenesis and management of gastric carcinoid tumours
-
Burkitt MD, Pritchard DM,. Pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 2006; 24: 1305-1320.
-
(2006)
Aliment Pharmacol Ther
, vol.24
, pp. 1305-1320
-
-
Burkitt, M.D.1
Pritchard, D.M.2
-
12
-
-
0030927818
-
Helicobacter pylori infection and chronic gastric acid hyposecretion
-
El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S, Williams C, Ardill JE, McColl KE,. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15-24.
-
(1997)
Gastroenterology
, vol.113
, pp. 15-24
-
-
El-Omar, E.M.1
Oien, K.2
El-Nujumi, A.3
Gillen, D.4
Wirz, A.5
Dahill, S.6
Williams, C.7
Ardill, J.E.8
McColl, K.E.9
-
13
-
-
0041919640
-
Cholecystokinin antagonists: Pharmacological and therapeutic potential
-
Herranz R,. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev 2003; 23: 559-605.
-
(2003)
Med Res Rev
, vol.23
, pp. 559-605
-
-
Herranz, R.1
-
14
-
-
14444288026
-
(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): A potent and orally active gastrin/CCK-B antagonist
-
Semple G, Ryder H, Rooker DP, Batt AR, Kendrick DA, Szelke M, Ohta M, Satoh M, Nishida A, Akuzawa S, Miyata K,. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. J Med Chem 1997; 40: 331-341.
-
(1997)
J Med Chem
, vol.40
, pp. 331-341
-
-
Semple, G.1
Ryder, H.2
Rooker, D.P.3
Batt, A.R.4
Kendrick, D.A.5
Szelke, M.6
Ohta, M.7
Satoh, M.8
Nishida, A.9
Akuzawa, S.10
Miyata, K.11
-
15
-
-
15144360265
-
Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula
-
Takemoto Y, Yuki H, Nishida A, Ito H, Kobayashi-Uchida A, Takinami Y, Akuzawa S, Ohta M, Satoh M, Semple G, Miyata K,. Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula. Arzneimittelforschung 1998; 48: 403-407.
-
(1998)
Arzneimittelforschung
, vol.48
, pp. 403-407
-
-
Takemoto, Y.1
Yuki, H.2
Nishida, A.3
Ito, H.4
Kobayashi-Uchida, A.5
Takinami, Y.6
Akuzawa, S.7
Ohta, M.8
Satoh, M.9
Semple, G.10
Miyata, K.11
-
16
-
-
8044235636
-
YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo
-
Takinami Y, Yuki H, Nishida A, Akuzawa S, Uchida A, Takemoto Y, Ohta M, Satoh M, Semple G, Miyata K,. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. Aliment Pharmacol Ther 1997; 11: 113-120.
-
(1997)
Aliment Pharmacol Ther
, vol.11
, pp. 113-120
-
-
Takinami, Y.1
Yuki, H.2
Nishida, A.3
Akuzawa, S.4
Uchida, A.5
Takemoto, Y.6
Ohta, M.7
Satoh, M.8
Semple, G.9
Miyata, K.10
-
17
-
-
0034073187
-
Long-lasting cholecystokinin(2) receptor blockade after a single subcutaneous injection of YF476 or YM022
-
Kitano M, Norlén P, Ding XQ, Nakamura S, Håkanson R,. Long-lasting cholecystokinin(2) receptor blockade after a single subcutaneous injection of YF476 or YM022. Br J Pharmacol 2000; 130: 699-705.
-
(2000)
Br J Pharmacol
, vol.130
, pp. 699-705
-
-
Kitano, M.1
Norlén, P.2
Ding, X.Q.3
Nakamura, S.4
Håkanson, R.5
-
18
-
-
0033962308
-
Effect of cholecystokinin-2 receptor blockade on rat stomach ECL cells. A histochemical, electron-microscopic and chemical study
-
Chen D, Zhao CM, Norlén P, Björkqvist M, Ding XQ, Kitano M, Håkanson R,. Effect of cholecystokinin-2 receptor blockade on rat stomach ECL cells. A histochemical, electron-microscopic and chemical study. Cell Tissue Res 2000; 299: 81-95.
-
(2000)
Cell Tissue Res
, vol.299
, pp. 81-95
-
-
Chen, D.1
Zhao, C.M.2
Norlén, P.3
Björkqvist, M.4
Ding, X.Q.5
Kitano, M.6
Håkanson, R.7
-
19
-
-
0347513474
-
Spontaneous ECL cell carcinomas in cotton rats: Natural course and prevention by a gastrin receptor antagonist
-
Martinsen TC, Kawase S, Håkanson R, Torp SH, Fossmark R, Qvigstad G, Sandvik AK, Waldum HL,. Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist. Carcinogenesis 2003; 24: 1887-1896.
-
(2003)
Carcinogenesis
, vol.24
, pp. 1887-1896
-
-
Martinsen, T.C.1
Kawase, S.2
Håkanson, R.3
Torp, S.H.4
Fossmark, R.5
Qvigstad, G.6
Sandvik, A.K.7
Waldum, H.L.8
-
20
-
-
77952673178
-
The CCK(2) receptor antagonist, YF476, inhibits mastomys ECL cell hyperplasia and gastric carcinoid tumor development
-
Kidd M, Siddique ZL, Drozdov I, Gustafsson BI, Camp RL, Black JW, Boyce M, Modlin IM,. The CCK(2) receptor antagonist, YF476, inhibits mastomys ECL cell hyperplasia and gastric carcinoid tumor development. Regul Pept 2010; 162: 52-60.
-
(2010)
Regul Pept
, vol.162
, pp. 52-60
-
-
Kidd, M.1
Siddique, Z.L.2
Drozdov, I.3
Gustafsson, B.I.4
Camp, R.L.5
Black, J.W.6
Boyce, M.7
Modlin, I.M.8
-
21
-
-
0030725409
-
Evaluation of three novel cholecystokinin-B/gastrin receptor antagonists: A study of their effects on rat stomach enterochromaffin-like cell activity
-
Ding XQ, Lindström E, Håkanson R,. Evaluation of three novel cholecystokinin-B/gastrin receptor antagonists: a study of their effects on rat stomach enterochromaffin-like cell activity. Pharmacol Toxicol 1997; 81: 232-237.
-
(1997)
Pharmacol Toxicol
, vol.81
, pp. 232-237
-
-
Ding, X.Q.1
Lindström, E.2
Håkanson, R.3
-
22
-
-
0034993548
-
Mobilization of rat stomach ECL-cell histamine in response to short- or long-term treatment with omeprazole and/or YF 476 studied by gastric submucosal microdialysis in conscious rats
-
Konagaya T, Bernsand M, Norlén P, Håkanson R,. Mobilization of rat stomach ECL-cell histamine in response to short- or long-term treatment with omeprazole and/or YF 476 studied by gastric submucosal microdialysis in conscious rats. Br J Pharmacol 2001; 133: 37-42.
-
(2001)
Br J Pharmacol
, vol.133
, pp. 37-42
-
-
Konagaya, T.1
Bernsand, M.2
Norlén, P.3
Håkanson, R.4
-
23
-
-
0037107415
-
Role of gastrin in the development of gastric mucosa, ECL cells and A-like cells in newborn and young rats
-
Björkqvist M, Dornonville de la Cour C, Zhao CM, Gagnemo-Persson R, Håkanson R, Norlén P,. Role of gastrin in the development of gastric mucosa, ECL cells and A-like cells in newborn and young rats. Regul Pept 2002; 108: 73-82.
-
(2002)
Regul Pept
, vol.108
, pp. 73-82
-
-
Björkqvist, M.1
Dornonville De La Cour, C.2
Zhao, C.M.3
Gagnemo-Persson, R.4
Håkanson, R.5
Norlén, P.6
-
24
-
-
79251551368
-
In vivo analysis of mouse gastrin gene regulation in enhanced GFP-BAC transgenic mice
-
Takaishi S, Shibata W, Tomita H, Jin G, Yang X, Ericksen R, Dubeykovskaya Z, Asfaha S, Quante M, Betz KS, Shulkes A, Wang TC,. In vivo analysis of mouse gastrin gene regulation in enhanced GFP-BAC transgenic mice. Am J Physiol Gastrointest Liver Physiol 2011; 300: G334-344.
-
(2011)
Am J Physiol Gastrointest Liver Physiol
, vol.300
, pp. G334-G344
-
-
Takaishi, S.1
Shibata, W.2
Tomita, H.3
Jin, G.4
Yang, X.5
Ericksen, R.6
Dubeykovskaya, Z.7
Asfaha, S.8
Quante, M.9
Betz, K.S.10
Shulkes, A.11
Wang, T.C.12
-
25
-
-
84862578459
-
Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects
-
Boyce M, David O, Darwin K, Mitchell T, Johnston A, Warrington S,. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Aliment Pharmacol Ther 2012; 36: 181-189.
-
(2012)
Aliment Pharmacol Ther
, vol.36
, pp. 181-189
-
-
Boyce, M.1
David, O.2
Darwin, K.3
Mitchell, T.4
Johnston, A.5
Warrington, S.6
-
26
-
-
84885044301
-
Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24h gastric acidity and gastrin in healthy subjects
-
Boyce M, Warrington S,. Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24h gastric acidity and gastrin in healthy subjects. Br J Clin Pharmacol 2013; 76: 680-688.
-
(2013)
Br J Clin Pharmacol
, vol.76
, pp. 680-688
-
-
Boyce, M.1
Warrington, S.2
-
27
-
-
84885085678
-
Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects
-
Boyce M, Warrington S, Black J,. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects. Br J Clin Pharmacol 2013; 76: 689-698.
-
(2013)
Br J Clin Pharmacol
, vol.76
, pp. 689-698
-
-
Boyce, M.1
Warrington, S.2
Black, J.3
-
28
-
-
13844297660
-
Patient reported outcomes in gastroesophageal reflux disease: An overview of available measures
-
Talley NJ, Wiklund I,. Patient reported outcomes in gastroesophageal reflux disease: an overview of available measures. Qual Life Res 2005; 14: 21-33.
-
(2005)
Qual Life Res
, vol.14
, pp. 21-33
-
-
Talley, N.J.1
Wiklund, I.2
-
29
-
-
0037024133
-
Validation of a liquid chromatographic-tandem mass spectrometric method for the measurement of (R)-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea (YF476) in human plasma
-
Redrup MJ, Leaf FC, Miyashita A, Watanabe T, Higuchi S, Chasseaud LF, Cheng KN,. Validation of a liquid chromatographic-tandem mass spectrometric method for the measurement of (R)-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea (YF476) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 772: 317-325.
-
(2002)
J Chromatogr B Analyt Technol Biomed Life Sci
, vol.772
, pp. 317-325
-
-
Redrup, M.J.1
Leaf, F.C.2
Miyashita, A.3
Watanabe, T.4
Higuchi, S.5
Chasseaud, L.F.6
Cheng, K.N.7
-
30
-
-
0035725743
-
Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy
-
Sanduleanu S, De Bruine A, Stridsberg M, Jonkers D, Biemond I, Hameeteman W, Lundqvist G, Stockbrugger RW,. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 2001; 31: 802-811.
-
(2001)
Eur J Clin Invest
, vol.31
, pp. 802-811
-
-
Sanduleanu, S.1
De Bruine, A.2
Stridsberg, M.3
Jonkers, D.4
Biemond, I.5
Hameeteman, W.6
Lundqvist, G.7
Stockbrugger, R.W.8
-
31
-
-
0005924729
-
Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: A case-control study
-
Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, Lamers C, Stockbrugger RW,. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999; 13: 145-153.
-
(1999)
Aliment Pharmacol Ther
, vol.13
, pp. 145-153
-
-
Sanduleanu, S.1
Stridsberg, M.2
Jonkers, D.3
Hameeteman, W.4
Biemond, I.5
Lundqvist, G.6
Lamers, C.7
Stockbrugger, R.W.8
-
32
-
-
78049498837
-
A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia
-
Jianu CS, Fossmark R, Syversen U, Hauso O, Waldum HL,. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia. Tumour Biol 2010; 31: 373-380.
-
(2010)
Tumour Biol
, vol.31
, pp. 373-380
-
-
Jianu, C.S.1
Fossmark, R.2
Syversen, U.3
Hauso, O.4
Waldum, H.L.5
-
33
-
-
84861829850
-
Long-term, open-label trial: Safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease
-
Brunner G, Athmann C, Schneider A,. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther 2012; 36: 37-47.
-
(2012)
Aliment Pharmacol Ther
, vol.36
, pp. 37-47
-
-
Brunner, G.1
Athmann, C.2
Schneider, A.3
-
34
-
-
0027200573
-
Time-dependent changes in enterochromaffin-like cell kinetics in stomach of hypergastrinemic rats
-
Håkanson R, Tielemans Y, Chen D, Andersson K, Mattsson H, Sundler F,. Time-dependent changes in enterochromaffin-like cell kinetics in stomach of hypergastrinemic rats. Gastroenterology 1993; 105: 15-21.
-
(1993)
Gastroenterology
, vol.105
, pp. 15-21
-
-
Håkanson, R.1
Tielemans, Y.2
Chen, D.3
Andersson, K.4
Mattsson, H.5
Sundler, F.6
-
35
-
-
0036307086
-
Effect of chronic hypergastrinemia on human enterochromaffin-like cells: Insights from patients with sporadic gastrinomas
-
Peghini PL, Annibale B, Azzoni C, Milione M, Corleto VD, Gibril F, Venzon DJ, Delle Fave G, Bordi C, Jensen RT,. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology 2002; 123: 68-85.
-
(2002)
Gastroenterology
, vol.123
, pp. 68-85
-
-
Peghini, P.L.1
Annibale, B.2
Azzoni, C.3
Milione, M.4
Corleto, V.D.5
Gibril, F.6
Venzon, D.J.7
Delle Fave, G.8
Bordi, C.9
Jensen, R.T.10
-
36
-
-
0033388447
-
Clinical and histopathological tumour progression in ECL cell carcinoids
-
Qvigstad G, Falkmer S, Westre B, Waldum HL,. Clinical and histopathological tumour progression in ECL cell carcinoids. APMIS 1999; 107: 1085-1092.
-
(1999)
APMIS
, vol.107
, pp. 1085-1092
-
-
Qvigstad, G.1
Falkmer, S.2
Westre, B.3
Waldum, H.L.4
-
37
-
-
33845388064
-
Systematic review: Rebound acid hypersecretion after therapy with proton pump inhibitors
-
Hunfeld NG, Geus WP, Kuipers EJ,. Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther 2007; 25: 39-46.
-
(2007)
Aliment Pharmacol Ther
, vol.25
, pp. 39-46
-
-
Hunfeld, N.G.1
Geus, W.P.2
Kuipers, E.J.3
-
38
-
-
0033995574
-
Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors?
-
Bonapace ES, Fisher RS, Parkman HP,. Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors? Dig Dis Sci 2000; 45: 34-39.
-
(2000)
Dig Dis Sci
, vol.45
, pp. 34-39
-
-
Bonapace, E.S.1
Fisher, R.S.2
Parkman, H.P.3
-
39
-
-
20444440611
-
Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer
-
Takaishi S, Cui G, Frederick DM, Carlson JE, Houghton J, Varro A, Dockray GJ, Ge Z, Whary MT, Rogers AB, Fox JG, Wang TC,. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer. Gastroenterology 2005; 128: 1965-1983.
-
(2005)
Gastroenterology
, vol.128
, pp. 1965-1983
-
-
Takaishi, S.1
Cui, G.2
Frederick, D.M.3
Carlson, J.E.4
Houghton, J.5
Varro, A.6
Dockray, G.J.7
Ge, Z.8
Whary, M.T.9
Rogers, A.B.10
Fox, J.G.11
Wang, T.C.12
-
40
-
-
0032771540
-
Review article: The pharmacokinetics of rabeprazole in health and disease
-
Swan SK, Hoyumpa AM, Merritt GJ,. Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther 1999; 13: (Suppl. 3): 11-17.
-
(1999)
Aliment Pharmacol Ther
, vol.13
, pp. 11-17
-
-
Swan, S.K.1
Hoyumpa, A.M.2
Merritt, G.J.3
-
41
-
-
33644931896
-
Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes
-
Miura M, Kagaya H, Tada H, Uno T, Yasui-Furukori N, Tateishi T, Suzuki T,. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. Br J Clin Pharmacol 2006; 61: 315-320.
-
(2006)
Br J Clin Pharmacol
, vol.61
, pp. 315-320
-
-
Miura, M.1
Kagaya, H.2
Tada, H.3
Uno, T.4
Yasui-Furukori, N.5
Tateishi, T.6
Suzuki, T.7
|